Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Accenture
Cerilliant
Covington
Baxter
Harvard Business School
Dow
Fuji
US Department of Justice

Generated: December 12, 2018

DrugPatentWatch Database Preview

FEMCON FE Drug Profile

« Back to Dashboard

Which patents cover Femcon Fe, and when can generic versions of Femcon Fe launch?

Femcon Fe is a drug marketed by Apil and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in FEMCON FE is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.

Drug patent expirations by year for FEMCON FE
Synonyms for FEMCON FE
(17 alpha)-17-hydroxy-19-norpregn-4-en-20-yn-3-one, mixture with (17 alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol
(17alpha)-17-Hydroxy-19-norpregn-4-en-20-yn-3-one, mixture with (17alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol
(1S,10R,11S,14R,15S)-14-ETHYNYL-15-METHYLTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-2,4,6-TRIENE-5,14-DIOL; (1S,2R,10R,11S,14R,15S)-14-ETHYNYL-14-HYDROXY-15-METHYLTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADEC-6-EN-5-ONE
(8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one; (8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanth
19-Nor-17-alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-, mixed with 19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yne-3,17-diol
37270-71-6
53464-69-0
AC1L1Y1Y
Alyacen 1/35
Alyacen 7/7/7
Aranelle
Balziva
Balziva-21
Balziva-28
Binovum
BREVICON 21-DAY
BREVICON 28-DAY
Brevion
C20H24O2.C20H26O2
Con-fer
Cyclafem 1/35
Cyclafem 7/7/7
DT 5061
DT 5062
DT-5061
DT-5062(1/35)
Duagynon
E-Con
Ethinyl estradiol mixture with norethindrone
ETHINYL ESTRADIOL; NORETHINDRONE
Ethinylestradiol-norethisterone mixt
Ethinylestradiol-norethisterone mixt.
Ethynylestradiol mixed with norethindrone
ethynylestradiol mixture with norethindrone
Eve 20
GENCEPT 10/11-21
GENCEPT 10/11-28
Gynovlar
Leena
Lo Minastrin Fe
LoDose
LS-178555
LS-97443
MODICON 21
MODICON 28
N.E.E. 1/35 21
N.E.E. 1/35 28
N049500000
Necon 7/7/7 28-Day Tablets
Neocon
Netasyn
NORCEPT-E 1/35 21
NORCEPT-E 1/35 28
NORETHIN 1/35E-21
NORETHIN 1/35E-28
Norethindron-ethinylestradiol mixt
Norethindron-ethinylestradiol mixt.
Norethindrone / Ethinyl estradiol
NORETHINDRONE AND ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)
Norethindrone Ethinyl Estradiol
Norethindrone mixed with ethynylestradiol
Norethindrone mixture with ethinyl estradiol
Norethindrone-ethinylestradiol mixt
Norethindrone-ethinylestradiol mixt.
Norethisterone mixed with ethinyl oestradiol
Norethisterone-ethinylestradiol mixt
Norethisterone-ethinylestradiol mixt.
Norethisterone-ethynylestradiol mixt
Norethisterone-ethynylestradiol mixt.
Norimen
Norimin
Norinyl 1 35
Norinyl 1-35
NORINYL 1+35 21-DAY
NORINYL 1+35 28-DAY
Norminest
Nortrel 0.5/35-21
Nortrel 0.5/35-28
Nortrel 1/35-21
Nortrel 1/35-28
Nortrel 7/7/7
Oestro-primolut
Ortho Novum 7-7-7
Ortho-Novum 1/35
ORTHO-NOVUM 1/35-21
ORTHO-NOVUM 1/35-28
Ortho-novum 10/11
ORTHO-NOVUM 10/11-21
Ortho-Novum 10/11-28
ORTHO-NOVUM 7/14-21
ORTHO-NOVUM 7/14-28
Ortho-novum 7/7/7
ORTHO-NOVUM 7/7/7-21
ORTHO-NOVUM 7/7/7-28
Ortho-Novum 777
Ovcon 35
Ovcon 50
OVCON-35
OVCON-50
Ovyrmen
Ovysmen
PL055333
Primidos
SCHEMBL3835489
SH 7.1122
SH B 259 AB
TRI-NORINYL 21-DAY
TRI-NORINYL 28-DAY
Trinovum
Zenchent
Zoran

US Patents and Regulatory Information for FEMCON FE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil FEMCON FE ethinyl estradiol; norethindrone TABLET, CHEWABLE;ORAL 021490-001 Nov 14, 2003 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for FEMCON FE
Drugname Dosage Strength RLD Date
➤ Subscribe Chewable Tablets 0.4 mg/0.035 mg ➤ Subscribe ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Federal Trade Commission
Mallinckrodt
Chinese Patent Office
Cantor Fitzgerald
Cerilliant
Express Scripts
US Department of Justice
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.